The effects of GLP‐1 RA on chronic inflammatory diseases, including nonalcoholic fatty liver disease and atherosclerosis, are mediated by reduced activity of inflammatory pathways, which may affect COVID‐19.56 Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.